387 related articles for article (PubMed ID: 21612474)
1. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
2. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy.
Kaufman DS; McDougal WS; Zietman AL; Harisinghani MG; Young RH
N Engl J Med; 2004 Jul; 351(2):171-8. PubMed ID: 15247358
[No Abstract] [Full Text] [Related]
3. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
Ogan K; Berger M; Ball R
J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
[No Abstract] [Full Text] [Related]
5. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
6. [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
Uphoff J; Woziwodzki J; Schattka SO; Kollias A
Aktuelle Urol; 2008 Sep; 39(5):373-7. PubMed ID: 18798127
[TBL] [Abstract][Full Text] [Related]
7. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
8. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
Moul JW; Zlotta AR
BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
[No Abstract] [Full Text] [Related]
9. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
10. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Daskivich TJ; Oh WK
Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
[TBL] [Abstract][Full Text] [Related]
11. Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer.
Curtis KK; Pruthi RK; Fonseca R; Gornet MK
Urology; 2007 Oct; 70(4):811.e5-8. PubMed ID: 17991572
[TBL] [Abstract][Full Text] [Related]
12. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R
Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169
[TBL] [Abstract][Full Text] [Related]
14. [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
Barbón JJ; González-Tuero J; Gay LL; Pérez-García FJ; Sampedro A
Arch Soc Esp Oftalmol; 2007 Nov; 82(11):715-7. PubMed ID: 17979041
[TBL] [Abstract][Full Text] [Related]
15. Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
Doyle-Lindrud S
Clin J Oncol Nurs; 2006 Oct; 10(5):565-6. PubMed ID: 17063610
[TBL] [Abstract][Full Text] [Related]
16. [Diferelin treatment of primary local and generalized cancer of the prostate].
Kolesnikov GP; Rusakov IG; Shaplygin LV; Voznesenskiĭ SA; Bystrov AA
Urologiia; 2001; (6):17-9. PubMed ID: 11785073
[No Abstract] [Full Text] [Related]
17. False elevations in prostate-specific antigen levels affecting patient management.
Kummar S; Shafi NQ
Clin Adv Hematol Oncol; 2004 Sep; 2(9):599-601; discussion 602. PubMed ID: 16163243
[No Abstract] [Full Text] [Related]
18. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.
Malone S; Perry G; Segal R; Dahrouge S; Crook J
BJU Int; 2005 Sep; 96(4):514-20. PubMed ID: 16104902
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
20. Case records of the Massachusetts General Hospital. Case 18-2007. A 54-year-old man with early-stage prostate cancer.
Kaufman DS; McDougal WS; Zietman AL; Young RH
N Engl J Med; 2007 Jun; 356(24):2515-20. PubMed ID: 17568033
[No Abstract] [Full Text] [Related]
[Next] [New Search]
